- In June 2024, Prevounce Health launched the Pylo GL1-LTE, a technologically advanced, cellular-connected blood glucose meter designed for remote patient monitoring. This device is rigorously tested and FDA-approved, ensuring high accuracy comparable to laboratory testing equipment1. It is widely available in the US and global markets, offering reliable data transmission through multiple cellular networks. The Pylo GL1-LTE integrates seamlessly with Prevounce's remote care management platform and other health software via the Pylo cloud API1. This launch represents a significant advancement in diabetes management, providing patients and healthcare providers with a dependable and user-friendly solution for real-time blood glucose monitoring
- In June 2024, the U.S. FDA approved Abbott's two new over-the-counter continuous glucose monitoring (CGM) devices, Libre Rio and Lingo. Libre Rio is designed for adults with Type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications1. Lingo, on the other hand, is aimed at consumers who want to improve their overall health and wellness by tracking glucose levels and providing personalized insights and coaching. Both devices are based on Abbott's world-leading FreeStyle Libre® sensing technology and are used by more than 6 million people globally
- In May 2024, Smart Meter launched the iGlucose Plus, a handheld glucose monitoring device designed for global use. This innovative device connects to smartphones and Wi-Fi systems, providing real-time blood glucose monitoring1. The iGlucose Plus features a color LED screen for easy viewing of instructions and results, and it automatically transmits data to healthcare providers via built-in cellular technology. This eliminates the need for manual syncing or pairing, making diabetes management more convenient and efficient1. The device also supports multiple languages and can receive notifications and reminders directly on the screen, enhancing user experience and adherence to testing protocols
Frequently Asked Questions
The U.S. is expected to dominate the global blood glucose monitoring system market. This is due to factors such as a high prevalence of diabetes, advanced healthcare infrastructure, and supportive reimbursement policies.
North America holds the largest share in the global blood glucose monitoring system market. This dominance is attributed to factors such as a high prevalence of diabetes, advanced healthcare infrastructure, and supportive reimbursement policies.
